IMPACT-CABG Trial: Implantation of CD133+ Stem Cells in Patients Undergoing Coronary Bypass Surgery—Presentation of the First Treated Patient
The IMPACT-CABG study is the first Canadian randomized-controlled phase II clinical trial aiming to assess the effect of intramyocardial (IM) injections of CD133+-selected stem cells in patients referred for coronary artery bypass graft (CABG) with a “chronic” myocardial infarction and persistent le...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Case Reports in Transplantation |
| Online Access: | http://dx.doi.org/10.1155/2011/685394 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566859445043200 |
|---|---|
| author | Jessica Forcillo Louis-Mathieu Stevens Samer Mansour Ignacio Prieto Denis-Claude Roy Nicolas Noiseux |
| author_facet | Jessica Forcillo Louis-Mathieu Stevens Samer Mansour Ignacio Prieto Denis-Claude Roy Nicolas Noiseux |
| author_sort | Jessica Forcillo |
| collection | DOAJ |
| description | The IMPACT-CABG study is the first Canadian randomized-controlled phase II clinical trial aiming to assess the effect of intramyocardial (IM) injections of CD133+-selected stem cells in patients referred for coronary artery bypass graft (CABG) with a “chronic” myocardial infarction and persistent left ventricular dysfunction. Patients are followed for 2 years with different imaging techniques including the stress magnetic resonance to evaluate the global and regional myocardial viability. Before the beginning of the randomization, the 5 first patients are treated in an open-label fashion to assess safety and feasibility of the IM CD133+ injections. Herein, we report the first Canadian patient treated with IM injection of CD133+ cells during CABG surgery as part of the IMPACT-CABG trial. |
| format | Article |
| id | doaj-art-e143d40423544d39a30af0ac59bfc12e |
| institution | Kabale University |
| issn | 2090-6943 2090-6951 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Transplantation |
| spelling | doaj-art-e143d40423544d39a30af0ac59bfc12e2025-02-03T01:03:10ZengWileyCase Reports in Transplantation2090-69432090-69512011-01-01201110.1155/2011/685394685394IMPACT-CABG Trial: Implantation of CD133+ Stem Cells in Patients Undergoing Coronary Bypass Surgery—Presentation of the First Treated PatientJessica Forcillo0Louis-Mathieu Stevens1Samer Mansour2Ignacio Prieto3Denis-Claude Roy4Nicolas Noiseux5Department of Cardiac Surgery, CHUM, 3840 Rue Saint-Urbain, Montréal, QC, H2W 1T7, CanadaDepartment of Cardiac Surgery, CHUM, 3840 Rue Saint-Urbain, Montréal, QC, H2W 1T7, CanadaSurgery Department, Université de Montréal, Montréal, QC, H3C 3J7, CanadaDepartment of Cardiac Surgery, CHUM, 3840 Rue Saint-Urbain, Montréal, QC, H2W 1T7, CanadaSurgery Department, Université de Montréal, Montréal, QC, H3C 3J7, CanadaDepartment of Cardiac Surgery, CHUM, 3840 Rue Saint-Urbain, Montréal, QC, H2W 1T7, CanadaThe IMPACT-CABG study is the first Canadian randomized-controlled phase II clinical trial aiming to assess the effect of intramyocardial (IM) injections of CD133+-selected stem cells in patients referred for coronary artery bypass graft (CABG) with a “chronic” myocardial infarction and persistent left ventricular dysfunction. Patients are followed for 2 years with different imaging techniques including the stress magnetic resonance to evaluate the global and regional myocardial viability. Before the beginning of the randomization, the 5 first patients are treated in an open-label fashion to assess safety and feasibility of the IM CD133+ injections. Herein, we report the first Canadian patient treated with IM injection of CD133+ cells during CABG surgery as part of the IMPACT-CABG trial.http://dx.doi.org/10.1155/2011/685394 |
| spellingShingle | Jessica Forcillo Louis-Mathieu Stevens Samer Mansour Ignacio Prieto Denis-Claude Roy Nicolas Noiseux IMPACT-CABG Trial: Implantation of CD133+ Stem Cells in Patients Undergoing Coronary Bypass Surgery—Presentation of the First Treated Patient Case Reports in Transplantation |
| title | IMPACT-CABG Trial: Implantation of CD133+ Stem Cells in Patients Undergoing Coronary Bypass Surgery—Presentation of the First Treated Patient |
| title_full | IMPACT-CABG Trial: Implantation of CD133+ Stem Cells in Patients Undergoing Coronary Bypass Surgery—Presentation of the First Treated Patient |
| title_fullStr | IMPACT-CABG Trial: Implantation of CD133+ Stem Cells in Patients Undergoing Coronary Bypass Surgery—Presentation of the First Treated Patient |
| title_full_unstemmed | IMPACT-CABG Trial: Implantation of CD133+ Stem Cells in Patients Undergoing Coronary Bypass Surgery—Presentation of the First Treated Patient |
| title_short | IMPACT-CABG Trial: Implantation of CD133+ Stem Cells in Patients Undergoing Coronary Bypass Surgery—Presentation of the First Treated Patient |
| title_sort | impact cabg trial implantation of cd133 stem cells in patients undergoing coronary bypass surgery presentation of the first treated patient |
| url | http://dx.doi.org/10.1155/2011/685394 |
| work_keys_str_mv | AT jessicaforcillo impactcabgtrialimplantationofcd133stemcellsinpatientsundergoingcoronarybypasssurgerypresentationofthefirsttreatedpatient AT louismathieustevens impactcabgtrialimplantationofcd133stemcellsinpatientsundergoingcoronarybypasssurgerypresentationofthefirsttreatedpatient AT samermansour impactcabgtrialimplantationofcd133stemcellsinpatientsundergoingcoronarybypasssurgerypresentationofthefirsttreatedpatient AT ignacioprieto impactcabgtrialimplantationofcd133stemcellsinpatientsundergoingcoronarybypasssurgerypresentationofthefirsttreatedpatient AT denisclauderoy impactcabgtrialimplantationofcd133stemcellsinpatientsundergoingcoronarybypasssurgerypresentationofthefirsttreatedpatient AT nicolasnoiseux impactcabgtrialimplantationofcd133stemcellsinpatientsundergoingcoronarybypasssurgerypresentationofthefirsttreatedpatient |